Skip to main
GILD

Gilead Sciences (GILD) Stock Forecast & Price Target

Gilead Sciences (GILD) Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 50%
Buy 31%
Hold 19%
Sell 0%
Strong Sell 0%

Bulls say

Gilead Sciences is a global biotechnology company with a strong portfolio in virology and infectious diseases, and a growing presence in the oncology market. The company's acquisition of Pharmasset brings rights to hepatitis C drug Sovaldi, which, along with newer combination therapies, remains a standard of care for the disease. Gilead's strong HIV franchise, led by drugs like Biktarvy and Descovy, and its expanding portfolio of oncology drugs, such as Yescarta, Tecartus, and Trodelvy, position the company for continued growth. Additionally, Gilead's commitment to diversity and sustainability efforts further support its long-term outlook.

Bears say

Gilead Sciences is facing potential competition in its HIV product portfolio as newer drugs, such as Biktarvy and Descovy, may face challenges from longer-acting combo regimens in the future. Additionally, the company's PrEP drug, Yeztugo, may require a more intensive loading regimen, limiting its use. Despite strong financial performance in the first quarter of 2026, Gilead's guidance for the full year reflects a degree of conservatism, likely due to potential pricing pressures from drug pricing agreements and ACA changes. The company's pipeline, while diverse, may face competition from new treatments in areas such as inflammatory diseases and oncology, potentially impacting future growth.

Gilead Sciences (GILD) has been analyzed by 16 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 31% recommend Buy, 19% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Gilead Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Gilead Sciences (GILD) Forecast

Analysts have given Gilead Sciences (GILD) a Buy based on their latest research and market trends.

According to 16 analysts, Gilead Sciences (GILD) has a Buy consensus rating as of Sep 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $156.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $156.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Gilead Sciences (GILD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.